GASTRIC MOTILITY DISORDER DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On February 12, 2024, Takeda, a pharmaceutical company stated that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only U.S. FDA-approved oral treatment for persons aged 11 and above with eosinophilic esophagitis (EoE).1 It will be accessible in convenient single-dose stick packs with 2 mg/10 mL by the end of February 2024.
• In December 2023, Vanda Pharmaceuticals Inc., a pharmaceutical company, stated that the U.S. FDA has accepted Vanda Pharmaceuticals Inc.’s New Drug Application (NDA) for tradipitant to treat gastroparesis symptoms. The U.S. FDA has established September 18, 2024 as the target deadline for its determination under the Prescription Drug User Fee Act (PDUFA).
• In April 2022, Ardelyx, Inc., a biopharmaceutical company founded with the mission of discovering, developing, and commercializing innovative first-in-class medicines that address significant unmet medical needs, announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is Ardelyx's first U.S. FDA-approved product.
• In February 2022, Evoke Pharma, Inc., a specialty pharmaceutical company, and EVERSANA Life Science Service LLC, an independent provider of global commercial services, extended their agreement to collaborate on the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the U.S. until the end of 2026. Gimoti remains the most unique product for treating diabetic gastroparesis symptoms.